Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_assertion type Assertion NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_head.
- NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_assertion description "[Daily or every-2-days intravenous treatment of SAR125844 promoted a dose-dependent tumor regression in MET-amplified human gastric cancer models at tolerated doses without treatment-related body weight loss.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_provenance.
- NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_assertion evidence source_evidence_literature NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_provenance.
- NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_assertion SIO_000772 25504634 NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_provenance.
- NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_assertion wasDerivedFrom befree-2016 NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_provenance.
- NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_assertion wasGeneratedBy ECO_0000203 NP1248066.RARq27AjDZSKRgs4713mBdDlTfg_as_dQ52g4H19hkOm4130_provenance.